Getz D, Lavid N, Barzani E. Research and development outputs in Israel, scientific reports, summary report for. Samuel Neman Institute, Technion. 2019;17–21.
Rubin EJ, Baden LR, Morrissey S. Audio interview: assessing vaccine safety. N Engl J Med. 2021;385:e37.
PubMed
Google Scholar
Rubin EJ, Baden LR, Morrissey S. Audio interview: the real-world effectiveness of Covid-19 vaccination. N Engl J Med. 2021;384:e40.
CAS
PubMed
Google Scholar
Meeting transcript, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting. 2021, 14–15 October.
Meeting transcript, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting. 2022, 6 April.
Meeting transcript, Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting. 2021, 17 September.
Frieden J. Fauci: 'Dramatic Data' From Israel Support COVID-19 Boosters. 2021; https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94344.
Zhu J, Liu W. A tale of two databases: the use of Web of Science and Scopus in academic papers. Scientometrics. 2020;123(1):321–35.
Google Scholar
Jappe A. Professional standards in bibliometric research evaluation? A meta-evaluation of European assessment practice 2005–2019. PLoS ONE. 2020;15(4):e0231735.
CAS
PubMed
PubMed Central
Google Scholar
Singh VK, Singh P, Karmakar M, Leta J, Mayr P. The journal coverage of Web of Science, Scopus and Dimensions: a comparative analysis. Scientometrics. 2021;126(6):5113–42.
Google Scholar
Goldshtein I, Steinberg DM, Kuint J, Chodick G, Segal Y, Ben David SS, et al. Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes. JAMA Pediatr. 2022;176(5):470–7.
PubMed
Google Scholar
Mittelman M, Magen O, Barda N, Dagan N, Oster HS, Leader A, et al. Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting. Blood. 2022;139(10):1439–51.
CAS
PubMed
PubMed Central
Google Scholar
Edelman-Klapper H, Zittan E, Shitrit AB, Rabinowitz KM, Goren I, Avni-Biron I, et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF alpha. Gastroenterology. 2022;162(2):454–67.
CAS
PubMed
Google Scholar
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science. 2022;375(6585):1151.
CAS
PubMed
PubMed Central
Google Scholar
Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis. 2022;22(3):357–66.
CAS
PubMed
Google Scholar
Ligumsky H, Safadi E, Etan T, Vaknin N, Waller M, Croll A, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine among actively treated cancer patients. J Natl Cancer Inst. 2022;114(2):203–9.
PubMed
Google Scholar
Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H, et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA. 2022;327(4):341–9.
CAS
PubMed
Google Scholar
Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139(5):678–85.
CAS
PubMed
PubMed Central
Google Scholar
Eifer M, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Shams J, et al. COVID-19 mRNA vaccination: age and immune status and its association with axillary lymph node PET/CT uptake. J Nucl Med. 2022;63(1):134–9.
CAS
PubMed
PubMed Central
Google Scholar
Elalamy I, Gerotziafas G, Alamowitch S, Laroche JP, Van Dreden P, Ageno W, et al. SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia. Thromb Haemost. 2021;121(08):982–91.
PubMed
PubMed Central
Google Scholar
Soyfer V, Gutfeld O, Shamai S, Schlocker A, Merimsky O. COVID-19 Vaccine-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys. 2021;110(4):957–61.
PubMed
PubMed Central
Google Scholar
Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021;195(2):186–93.
CAS
PubMed
PubMed Central
Google Scholar
Peled Y, Ram E, Lavee J, Segev A, Matezki S, Wieder-Finesod A, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2022;41(2):148–57.
PubMed
Google Scholar
Munitz A, Yechezkel M, Dickstein Y, Yamin D, Gerlic M. BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel. Cell Rep Med. 2021;2(5):100264.
CAS
PubMed
PubMed Central
Google Scholar
Furer V, Rondaan C, Agmon-Levin N, van Assen S, Bijl M, Kapetanovic MC, et al. Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open. 2021;7(1):e001594.
PubMed
Google Scholar
Ishay Y, Kenig A, Tsemach-Toren T, Amer R, Rubin L, Hershkovitz Y, et al. Autoimmune phenomena following SARS-CoV-2 vaccination. Int Immunopharmacol. 2021;99:107970.
CAS
PubMed
PubMed Central
Google Scholar
Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology. 2021;300(3):E345–7.
PubMed
Google Scholar
Shemer A, Pras E, Einan-Lifshitz A, Dubinsky-Pertzov B, Hecht I. Association of COVID-19 vaccination and facial nerve palsy a case-control study. JAMA Otolaryngol Head Neck Surg. 2021;147(8):739–43.
PubMed
PubMed Central
Google Scholar
Milman O, Yelin I, Aharony N, Katz R, Herzel E, Ben-Tov A, et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat Med. 2021;27(8):1367.
CAS
PubMed
Google Scholar
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine. JAMA Intern Med. 2022;182(2):179–84.
CAS
PubMed
Google Scholar
Ben Zadok OI, Shaul AA, Ben-Avraham B, Yaari V, Ben Zvi H, Shostak Y, et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients—a prospective cohort study. Eur J Heart Fail. 2021;23(9):1555–9.
Google Scholar
Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw Open. 2021;4(6):e2115985.
PubMed
PubMed Central
Google Scholar
Beharier O, Mayo RP, Raz T, Sacks KN, Schreiber L, Suissa-Cohen Y, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest. 2021;131(13):0319.
Google Scholar
Peretz SB, Regev N, Novick L, Nachshol M, Goffer E, Ben-David A, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. Ultrasound Obstet Gynecol. 2021;58(3):450–6.
Google Scholar
Green MS, Abdullah R, Vered S, Nitzan D. A study of ethnic, gender and educational differences in attitudes toward COVID-19 vaccines in Israel—implications for vaccination implementation policies. Isr J Health Policy Res. 2021. https://doi.org/10.1186/s13584-021-00458-w.
Article
PubMed
PubMed Central
Google Scholar
Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [F-18]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021;48(6):1854–63.
CAS
PubMed
PubMed Central
Google Scholar
Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399(10328):924–44.
CAS
PubMed
PubMed Central
Google Scholar
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7(3):e001814.
PubMed
Google Scholar
Brill L, Rechtman A, Zveik O, Haham N, Oiknine-Djian E, Wolf DG, et al. Humoral and T-cell response to SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021;78(12):1510–4.
PubMed
Google Scholar
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Alroy-Preis S, et al. Protection against Covid-19 by BNT162b2 booster across age groups. N Engl J Med. 2021;385(26):2421–30.
CAS
PubMed
Google Scholar
Israel A, Shenhar Y, Green I, Merzon E, Golan-Cohen A, Schaeffer AA, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Vaccines. 2022;10(1):64.
CAS
Google Scholar
Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. JAMA. 2021;326(8):728–35.
CAS
PubMed
PubMed Central
Google Scholar
Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5(16):3053–61.
CAS
PubMed
PubMed Central
Google Scholar
Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 2021;27(10):1693.
CAS
PubMed
Google Scholar
Tzarfati KH, Gutwein O, Apel A, Rahimi-Levene N, Sadovnik M, Harel L, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021;96(10):1195–203.
Google Scholar
Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Eurosurveillance. 2021;26(26):0557.
Google Scholar
Goshen-Lago T, Waldhorn I, Holland R, Szwarcwort-Cohen M, Reiner-Benaim A, Shachor-Meyouhas Y, et al. Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(10):1507–13.
PubMed
Google Scholar
Levine-Tiefenbrun M, Yelin I, Alapi H, Katz R, Herzel E, Kuint J, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12):2108.
CAS
PubMed
Google Scholar
Furer V, Zisman D, Kibari A, Rimar D, Paran Y, Elkayam O. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology. 2021;60:SI90–5.
CAS
PubMed
Google Scholar
Lebedev L, Sapojnikov M, Wechsler A, Varadi-Levi R, Zamir D, Tobar A, et al. Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(1):142–5.
CAS
PubMed
PubMed Central
Google Scholar
Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–51.
CAS
PubMed
PubMed Central
Google Scholar
Peled Y, Ram E, Lavee J, Sternik L, Segev A, Wieder-Finesod A, et al. BNT162b2 vaccination in heart transplant recipients: clinical experience and antibody response. J Heart Lung Transplant. 2021;40(8):759–62.
PubMed
PubMed Central
Google Scholar
Chodick G, Tene L, Rotem RS, Patalon T, Gazit S, Ben-Tov A, et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin Infect Dis. 2022;74(3):472–8.
CAS
PubMed
Google Scholar
Mizrahi B, Lotan R, Kalkstein N, Peretz A, Perez G, Ben-Tov A, et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun. 2021. https://doi.org/10.1038/s41467-021-26672-3.
Article
PubMed
PubMed Central
Google Scholar
Hagin D, Freund T, Navon M, Halperin T, Adir D, Marom R, et al. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity. J Allergy Clin Immunol. 2021;148(3):739–49.
CAS
PubMed
PubMed Central
Google Scholar
Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162b2 vaccine booster and mortality due to Covid-19. N Engl J Med. 2021;385(26):2413–20.
CAS
PubMed
Google Scholar
Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat Med. 2021;27(6):1055.
CAS
PubMed
Google Scholar
Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, et al. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler J. 2021;27(6):864–70.
CAS
Google Scholar
Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis. 2021;80(10):1317–21.
CAS
PubMed
Google Scholar
Shmueli L. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health. 2021. https://doi.org/10.1186/s12889-021-10816-7.
Article
PubMed
PubMed Central
Google Scholar
Kuzmina A, Khalaila Y, Voloshin O, Keren-Naus A, Boehm-Cohen L, Raviv Y, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. Cell Host Microbe. 2021;29(4):522.
CAS
PubMed
PubMed Central
Google Scholar
Rozen-Zvi B, Yahav D, Agur T, Zingerman B, Ben-Zvi H, Atamna A, et al. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Clin Microbiol Infect. 2021;27(8):1173.
PubMed Central
Google Scholar
Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med. 2021;9(9):999–1009.
CAS
PubMed
PubMed Central
Google Scholar
Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, et al. Association between vaccination With BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021;325(24):2457–65.
CAS
PubMed
Google Scholar
Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27(11):1652–7.
CAS
PubMed
PubMed Central
Google Scholar
Abu Mouch S, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39(29):3790–3.
CAS
PubMed
PubMed Central
Google Scholar
Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021;7(8):1133–40.
PubMed
Google Scholar
Rosen B, Waitzberg R, Israeli A. Israel’s rapid rollout of vaccinations for COVID-19. Isr J Health Policy Res. 2021. https://doi.org/10.1186/s13584-021-00440-6.
Article
PubMed
PubMed Central
Google Scholar
Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8):1379.
CAS
PubMed
PubMed Central
Google Scholar
Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, et al. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines. 2021;9(5):435.
CAS
PubMed
PubMed Central
Google Scholar
Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance. 2021. https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096.
Article
PubMed
PubMed Central
Google Scholar
Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385(2):179–86.
CAS
PubMed
Google Scholar
Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75(2):435–8.
CAS
PubMed
PubMed Central
Google Scholar
Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–9.
CAS
PubMed
Google Scholar
Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021;16(7):1037–42.
CAS
PubMed
PubMed Central
Google Scholar
Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140–9.
CAS
PubMed
Google Scholar
Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:175628642110128.
Google Scholar
Grupper A, Rabinowich L, Schwartz D, Schwartz IF, Ben-Yehoyada M, Shashar M, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719–26.
CAS
PubMed
PubMed Central
Google Scholar
Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis. 2021;80(10):1330–8.
CAS
PubMed
Google Scholar
Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021;27(5):790.
CAS
PubMed
Google Scholar
Barda N, Dagan N, Cohen C, Hernan MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398(10316):2093–100.
CAS
PubMed
PubMed Central
Google Scholar
Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–90.
CAS
PubMed
Google Scholar
Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):E85.
CAS
PubMed
Google Scholar
Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–73.
CAS
PubMed
PubMed Central
Google Scholar
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N Engl J Med. 2021;385(15):1393–400.
CAS
PubMed
Google Scholar
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):E84.
CAS
PubMed
Google Scholar
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29.
CAS
PubMed
PubMed Central
Google Scholar
Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–84.
CAS
PubMed
Google Scholar
Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775–9.
CAS
PubMed
PubMed Central
Google Scholar
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23.
CAS
PubMed
Google Scholar
Rosen B, Waitzberg R, Israeli A, Hartal M, Davidovitch N. Addressing vaccine hesitancy and access barriers to achieve persistent progress in Israel’s COVID-19 vaccination program. Isr J Health Policy Res. 2021;10(1):1–20.
Google Scholar
TOI staff. Israel becomes first country in world to give COVID boosters to over-50s. Times of Israel 2021 13 August.
Delkic M. Your Tuesday Briefing: Israel Collects Data on Fourth Dose. The New York Times.
Gold H. What the world could learn from Israel's Covid-19 vaccine booster rollout. 2021. https://edition.cnn.com/2021/11/24/health/israel-covid-booster-lessons-intl-cmd/index.html.
Jaffe-Hoffman M. Why is Israel mass vaccinating teens when WHO says not to?—analysis. Jerusalem Post 2021 5 July.
Balicer RD, Afek A. Digital health nation: Israel’s global big data innovation hub. The Lancet. 2017;389(10088):2451–3.
Google Scholar
Kotler M. Gift to propel precision medicine research, training at Harvard Medical School, Clalit Research Institute. 2021.
Palayew A, Norgaard O, Safreed-Harmon K, Andersen TH, Rasmussen LN, Lazarus JV. Pandemic publishing poses a new COVID-19 challenge. Nat Hum Behav. 2020;4(7):666–9.
PubMed
Google Scholar
Else H. How a torrent of COVID science changed research publishing–in seven charts. Nature. 2020;588(7839):553–4.
CAS
PubMed
Google Scholar
Rubin EJ, Baden LR, Morrissey S. COVID-19: why we publish what we do. N Engl J Med. 2022;386:e38.
CAS
PubMed
Google Scholar
Reis B, Barda N, Leshchinsky M, Kepten E, Hernan MA, Lipsitch M, et al. Effectiveness of BNT162b2 vaccine against delta variant in adolescents. N Engl J Med. 2021;385(22):2101–3.
PubMed
Google Scholar
Cohen-Stavi CJ, Magen O, Barda N, Yaron S, Peretz A, Netzer D, et al. BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age. N Engl J Med.
Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernan MA, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2022;386(17):1603–14.
CAS
PubMed
Google Scholar
Barda N, Dagan N, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting REPLY. N Engl J Med. 2021;384(20):1970.
PubMed
Google Scholar
Benenson S, Oster Y, Cohen MJ, Nir-Paz R. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers. N Engl J Med. 2021;384(18):1775–7.
PubMed
Google Scholar
Hammerman A, Sergienko R, Friger M, Beckenstein T, Peretz A, Netzer D, et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med. 2022;386(13):1221–9.
CAS
PubMed
Google Scholar
Dagan N, Barda N, Balicer RD. Adverse effects after BNT162b2 vaccine and SARS-CoV-2 infection, according to age and sex. N Engl J Med. 2021;385(24):2299.
CAS
PubMed
Google Scholar
Arbel R, Sergienko R, Hammerman A. BNT162b2 vaccine booster and Covid-19 mortality. N Engl J Med. 2022;386(10):1000–1.
PubMed
Google Scholar
Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N Engl J Med. 2022;386(5):492–4.
PubMed
Google Scholar
Muhsen K, Maimon N, Mizrahi A, Varticovschi B, Bodenheimer O, Gelbshtein U, et al. Effects of BNT162b2 Covid-19 vaccine booster in long-term care facilities in Israel. N Engl J Med. 2022;386(4):399–401.
CAS
PubMed
Google Scholar
Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against omicron. N Engl J Med. 2022;386(14):1377–80.
PubMed
Google Scholar
Mevorach D, Anis E, Cedar N, Hasin T, Bromberg M, Goldberg L, et al. Myocarditis after BNT162b2 vaccination in Israeli adolescents. N Engl J Med. 2022;386(10):998–9.
PubMed
Google Scholar
Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med. 2022;386(18):1712–20.
CAS
PubMed
Google Scholar
Lustig Y, Nemet I, Kliker L, Zuckerman N, Yishai R, Alroy-Preis S, et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med. 2021;384(25):2453–4.
CAS
PubMed
Google Scholar
Rastmanesh R, Gonen T, Lustig Y, Regev-Yochay G. Covid-19 Infections in Vaccinated Health Care Workers. N Engl J Med.
Amit S, Gonen T, Regev-Yochay G. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(17):1629–30.
Google Scholar
Waitzberg R, Rosen B. Israel: Health Systems in Transition Profile. 2022;2022.
Estrin D. Vaccines For Data: Israel’s Pfizer Deal Drives Quick Rollout—And Privacy Worries. 2021. https://www.wuft.org/nation-world/2021/01/31/vaccines-for-data-israels-pfizer-deal-drives-quick-rollout-and-privacy-worries/.
Beyar R, Zeevi B, Rechavi G. Israel: a start-up life science nation. Lancet. 2017;389(10088):2563–9.
PubMed
Google Scholar
Aviv-Reuven S, Rosenfeld A. Publication patterns’ changes due to the COVID-19 pandemic: a longitudinal and short-term scientometric analysis. Scientometrics. 2021;126(8):6761–84.
CAS
PubMed
PubMed Central
Google Scholar
Abramo G, D’Angelo CA, Di Costa F. How the Covid-19 crisis shaped research collaboration behaviour. Scientometrics 2022:1–19.
Bodas M, Peleg K. Income assurances are a crucial factor in determining public compliance with self-isolation regulations during the COVID-19 outbreak–cohort study in Israel. Isr J Health Policy Res. 2020;9:54.
PubMed
PubMed Central
Google Scholar
Clalit Research Institute. Clalit Research Institute wins 1st place in the NEJM SPRINT Challenge for its individualized treatment decision tool. 2017. http://clalitresearch.org/clalit-research-institute-wins-1st-place-in-the-nejm-sprint-challenge-for-its-individualized-treatment-decision-tool/.
Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252–60.
CAS
PubMed
Google Scholar